Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Small Cell Lung Carcinoma 16Breast Neoplasms 13Sarcoma 10Carcinoma, Hepatocellular 8Esophageal Squamous Cell Carcinoma 7Lung Neoplasms 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Carcinoma 5Stomach Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Thyroid Neoplasms 3Recurrence 3Paraganglioma 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2

Interventions

Ocoxin 2niraparib 1anlotinib 1Thalidomide 1Sunitinib 1Spironolactone 1Paclitaxel 1Melphalan 1Leuprolide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CP protocol 1Bortezomib 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endocrine System Diseases × anlotinib × Clear all
NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
56 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡